Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook


Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its third quarter ended September 30, 2021 and updated its financial outlook for the full year ending December 31, 2021.

Third Quarter 2021 Financial Summary:

Third Quarter 2021 Operating Highlights:

Management Comments:

"We are excited by our team's impressive execution during the third quarter, which enabled us to achieve 88% growth year-over-year in sales of our Advanced Energy products. Our Advanced Energy sales growth was driven primarily by strong, global utilization of our Advanced Energy handpieces, with global handpiece sales increasing more than 100% year-over-year. We also saw global Advanced Energy generator sales increase by more than 70% year-over-year, primarily reflecting healthy adoption of our Renuvion® technology in the U.S. cosmetic surgery market."

Mr. Goodwin continued: "We are raising our 2021 financial outlook today in light of our stronger-than-anticipated performance that we achieved in the third quarter. Looking ahead, our financial outlook continues to reflect our expectations for continued improvement in the global capital equipment environment, coupled with strong utilization trends from our existing customers, during the fourth quarter. We expect to bring 2021 to a strong close as we continue to raise awareness of our innovative Helium Plasma Technology, expand our share of the multi-billion global cosmetic surgery market and enhance the foundation for strong, sustainable growth in the years ahead."

The following tables present revenue by reportable segment and geography:

 

 

Three Months Ended
September 30,

 

Increase/Decrease

 

Nine Months Ended
September 30,

 

Increase/Decrease

(In thousands)

 

2021

 

2020

 

$ Change

 

% Change

 

2021

 

2020

 

$ Change

 

% Change

Advanced Energy

 

$

10,313

 

 

$

5,479

 

 

$

4,834

 

 

88.2

%

 

$

27,951

 

 

$

12,332

 

 

$

15,619

 

 

126.7

%

OEM

 

1,518

 

 

1,475

 

 

43

 

 

2.9

%

 

3,742

 

 

3,915

 

 

(173

)

 

(4.4

)%

Total

 

$

11,831

 

 

$

6,954

 

 

$

4,877

 

 

70.1

%

 

$

31,693

 

 

$

16,247

 

 

$

15,446

 

 

95.1

%

 

 

Three Months Ended
September 30,

 

Increase/Decrease

 

Nine Months Ended
September 30,

 

Increase/Decrease

(In thousands)

 

2020

 

2019

 

$ Change

 

% Change

 

2020

 

2019

 

$ Change

 

% Change

Domestic

 

$

7,911

 

 

$

5,214

 

 

$

2,697

 

 

51.7

%

 

$

20,860

 

 

$

12,225

 

 

$

8,635

 

 

70.6

%

International

 

3,920

 

 

1,740

 

 

2,180

 

 

125.3

%

 

10,833

 

 

4,022

 

 

6,811

 

 

169.3

%

Total

 

$

11,831

 

 

$

6,954

 

 

$

4,877

 

 

70.1

%

 

$

31,693

 

 

$

16,247

 

 

$

15,446

 

 

95.1

%

Third Quarter 2021 Results:

Total revenue for the three months ended September 30, 2021 increased $4.9 million, or 70%, to $11.8 million, compared to $7.0 million in the prior year period. Advanced Energy segment sales increased $4.8 million, or 88% year-over-year, to $10.3 million, compared to $5.5 million in the prior year period. OEM segment sales increased 3% year-over-year. For the third quarter 2021, revenue in the United States increased $2.7 million, or 52% year-over-year, to $7.9 million, and international revenue increased $2.2 million, or 125% year-over-year, to $3.9 million. In the third quarter of 2021, total revenue growth was primarily driven by increased global utilization-based demand for handpieces and adoption of generators, despite continued headwinds related to the COVID-19 pandemic in certain geographic regions. COVID-19 related headwinds were relatively less severe on a global basis in the third quarter of 2021, compared to the prior year period.

Gross profit for the three months ended September 30, 2021, increased $3.3 million, or 70% year-over-year, to $8.1 million, compared to $4.7 million in the prior year period. Gross margin for the three months ended September 30, 2021, was 68.1%, compared to 67.9% for the same period in 2020. The increase in profit margins for the three months ended September 30, 2021 from the prior year period is primarily attributable to sales mix between the Advanced Energy and OEM segments, partially offset by product and geographic mix within the Advanced Energy segment and higher inbound shipping costs.

Operating expenses for the third quarter of 2021 increased $2.9 million, or 32% year-over-year, to $12.0 million, compared to $9.1 million for the third quarter of 2020. The year-over-year change in operating expenses was driven by a $1.9 million increase in selling, general and administrative expenses, a $0.7 million increase in salaries and related costs, a $0.2 million increase in professional services and a $0.1 million increase in research and development expenses.

Income tax expense for the third quarter of 2021 was $0.1 million, compared to an income tax benefit of $0.7 million for the third quarter of 2020. The year-over-year change in income tax expense (benefit) was primarily due to the net operating loss carryback recognized in the third quarter of 2020, which did not impact income tax expense in the third quarter of 2021.

Net loss attributable to stockholders for third quarter of 2021 was $4.2 million, or $0.12 per share, compared to a net loss of $3.7 million, or $0.11 per share, for the third quarter of 2020. Net loss attributable to stockholders in the third quarter of 2020 included an income tax benefit of $0.7 million.

First Nine Months of 2021 Results:

Total revenue for the nine months ended September 30, 2021 increased $15.4 million, or 95%, to $31.7 million, compared to $16.2 million in the prior year period. Advanced Energy segment sales increased $15.6 million, or 127% year-over-year, to $28.0 million, compared to $12.3 million in the prior year period. OEM segment sales decreased $0.2 million, or 4% year-over-year, to $3.7 million, compared to $3.9 million in the prior year period. For the nine months ended September 30, 2021, revenue in the United States increased $8.6 million, or 71% year-over-year, to $20.9 million, and international revenue increased $6.8 million, or 169% year-over-year, to $10.8 million.

Net loss attributable to stockholders for the nine months ended September 30, 2021 was $13.2 million, or $0.38 per share, compared to a net loss of $10.4 million, or $0.30 per share, for the nine months ended September 30, 2020. Net loss attributable to stockholders for the nine months ended September 30, 2020 included an income tax benefit of $7.1 million.

Full Year 2021 Financial Outlook:

The Company is updating financial guidance for the year ending December 31, 2021 to:

Conference Call Details:

Management will host a conference call at 5:00 p.m. Eastern Time on November 11, 2021 to discuss the results of the quarter and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13723897. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company's website and at:

https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/46871/indexl.html

A telephonic replay will be available approximately two hours after the end of the call through November 25, 2021. The replay can be accessed by dialing 877-660-6853 for U.S. callers or 201-612-7415 for international callers and using the replay access code: 13723897. The webcast will be archived on the Investor Relations section of the Company's website.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The Company's Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10-K for the year ended December 31, 2020. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. 

APYX MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

Nine months ended
September 30,

 

 

2021

 

2020

 

2021

 

2020

Sales

 

$

11,831

 

 

$

6,954

 

 

$

31,693

 

 

$

16,247

 

Cost of sales

 

3,775

 

 

2,229

 

 

10,243

 

 

6,444

 

Gross profit

 

8,056

 

 

4,725

 

 

21,450

 

 

9,803

 

Other costs and expenses:

 

 

 

 

 

 

 

 

Research and development

 

1,175

 

 

1,047

 

 

3,374

 

 

3,002

 

Professional services

 

2,032

 

 

1,835

 

 

5,442

 

 

5,882

 

Salaries and related costs

 

4,206

 

 

3,508

 

 

12,794

 

 

10,258

 

Selling, general and administrative

 

4,611

 

 

2,706

 

 

12,596

 

 

8,691

 

Total other costs and expenses

 

12,024

 

 

9,096

 

 

34,206

 

 

27,833

 

Loss from operations

 

(3,968

)

 

(4,371

)

 

(12,756

)

 

(18,030

)

Interest income

 

2

 

 

10

 

 

9

 

 

233

 

Interest expense

 

(3

)

 

(25

)

 

(9

)

 

(39

)

Other (loss) income, net

 

(192

)

 

(63

)

 

(188

)

 

349

 

Total other (loss) income, net

 

(193

)

 

(78

)

 

(188

)

 

543

 

Loss before income taxes

 

(4,161

)

 

(4,449

)

 

(12,944

)

 

(17,487

)

Income tax expense (benefit)

 

73

 

 

(715

)

 

246

 

 

(7,112

)

Net loss

 

(4,234

)

 

(3,734

)

 

(13,190

)

 

(10,375

)

Net loss attributable to non-controlling interest

 

(12

)

 

(6

)

 

(21

)

 

(6

)

Net loss attributable to stockholders

 

$

(4,222

)

 

$

(3,728

)

 

$

(13,169

)

 

$

(10,369

)

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

 

Basic and Diluted

 

$

(0.12

)

 

$

(0.11

)

 

$

(0.38

)

 

$

(0.30

)

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding - basic and diluted

 

34,330

 

 

34,216

 

 

34,318

 

 

34,193

 

APYX MEDICAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 
   

September 30,
2021
(Unaudited)

 

December 31,
2020

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

30,898

 

 

$

41,915

 

Trade accounts receivable, net of allowance of $360 and $300

 

11,444

 

 

8,399

 

Income tax receivables

 

7,654

 

 

7,654

 

Other receivables

 

873

 

 

1,275

 

Inventories, net of provision for obsolescence of $303 and $388

 

6,040

 

 

4,051

 

Prepaid expenses and other current assets

 

2,967

 

 

2,795

 

Total current assets

 

59,876

 

 

66,089

 

Property and equipment, net

 

6,412

 

 

6,541

 

Operating lease right-of-use assets

 

152

 

 

237

 

Finance lease right-of-use assets

 

274

 

 

437

 

Other assets

 

1,055

 

 

807

 

Total assets

 

$

67,769

 

 

$

74,111

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

3,044

 

 

$

1,511

 

Accrued expenses and other liabilities

 

8,324

 

 

7,278

 

Current portion of operating lease liabilities

 

125

 

 

126

 

Current portion of finance lease liabilities

 

218

 

 

238

 

Total current liabilities

 

11,711

 

 

9,153

 

Long-term operating lease liabilities

 

30

 

 

129

 

Long-term finance lease liabilities

 

22

 

 

183

 

Contract liabilities

 

1,200

 

 

621

 

Other liabilities

 

146

 

 

166

 

Total liabilities

 

13,109

 

 

10,252

 

EQUITY

 

 

 

 

Common stock, $0.001 par value; 75,000,000 shares authorized; 34,339,533 issued and outstanding as of September 30, 2021, and 34,289,222 outstanding as of December 31, 2020

 

34

 

 

34

 

Additional paid-in capital

 

64,862

 

 

61,066

 

(Accumulated deficit) retained earnings

 

(10,548

)

 

2,621

 

Total stockholders' equity

 

54,348

 

 

63,721

 

Non-controlling interest

 

312

 

 

138

 

Total equity

 

54,660

 

 

63,859

 

Total liabilities and equity

 

$

67,769

 

 

$

74,111

 

APYX MEDICAL CORPORATION

RECONCILIATION OF GAAP NET LOSS RESULTS TO NON-GAAP ADJUSTED EBITDA

(Unaudited)

Use of Non-GAAP Financial Measure

We present the following non-GAAP measure because we believe such measure is a useful indicator of our operating performance. Our management uses this non-GAAP measure principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period.

The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net income (loss) attributable to stockholders (GAAP) plus income tax expense (benefit), interest, depreciation and amortization, and stock-based compensation expense.

(In thousands)

 

Three Months Ended
September 30,

 

Nine months ended
September 30,

 

 

2021

 

2020

 

2021

 

2020

Net loss attributable to stockholders

 

$

(4,222

)

 

$

(3,728

)

 

$

(13,169

)

 

$

(10,369

)

Interest income

 

(2

)

 

(10

)

 

(9

)

 

(233

)

Interest expense

 

3

 

 

25

 

 

9

 

 

39

 

Income tax expense (benefit)

 

73

 

 

(715

)

 

246

 

 

(7,112

)

Depreciation and amortization

 

234

 

 

223

 

 

674

 

 

662

 

Stock based compensation

 

1,184

 

 

1,063

 

 

3,747

 

 

3,209

 

Adjusted EBITDA

 

$

(2,730

)

 

$

(3,142

)

 

$

(8,502

)

 

$

(13,804

)

The following unaudited table presents a reconciliation of net loss attributable to stockholders to Adjusted EBITDA loss for the year ending December 31, 2021. The reconciliation assumes the mid-point of the Adjusted EBITDA loss range and the midpoint of each component of the reconciliation, corresponding to guidance for GAAP net loss attributable to stockholders of $17.8 million to $17.2 million for the year ending December 31, 2021.

(In millions)

 

Year Ending December 31, 2021

Net loss attributable to stockholders

 

$

(17.5

)

Interest income

 

?

 

Interest expense

 

?

 

Income tax expense

 

0.3

 

Depreciation and amortization

 

0.9

 

Stock based compensation

 

5.2

 

Adjusted EBITDA

 

$

(11.2

)

Note: figures may not sum to totals due to rounding

   

 


These press releases may also interest you

at 11:30
As per Zion Market Research study, The Electronic Display Market was worth around USD 551.8 billion in 2021 and is estimated to grow to about USD 1,026.5 billion by 2028, with a compound annual growth rate (CAGR) of approximately 10.9 percent over...

at 11:25
AM Best benchmarking analysis of rated U.S. life/annuity (L/A) insurance companies showed that not only did COVID-19 have a limited impact on operating performance, those insurers with an assessment of very strong have not reported an operating loss...

at 11:25
The "Global Medical Disinfectant Wipes Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type, By Application (Hospitals & Clinics, Dental Clinic, Nursing Home, and Others), By Regional Outlook and Forecast, 2021-2027"...

at 11:10
The "Global Loyalty Programs Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Loyalty Programs Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2022 Update" report has been...

at 11:10
U.S. consumers are seeking faster payments in more areas of their increasingly on-demand lives, with four out of five saying they are interested in faster options to pay businesses, according to a survey released today by the Federal Reserve Banks....

at 11:10
The "Asia Pacific Loyalty Programs Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Loyalty Programs Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2022 Update" report has...



News published on 11 november 2021 at 16:10 and distributed by: